Primary and secondary prevention of cardiovascular disease in patients with hyperlipoproteinemia (a)

Ridker P, Hennekens C, Stampfer M (1993) A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA 270:2195–2199

Emerging Risk Factors Collaboration (2009) Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 303:412–423

Nordestgaard B, Chapman M, Ray K et al (2010) Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 31:2844–2853

Yusuf S, Lonn E, Pais P et al (2016) Blood-pressure and cholesterol lowering in persons without cardiovascular disease. N Engl J Med 374:2032–2043

Yusuf S, Bosch J, Dagenais G et al (2016) Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med 374:2021–2031

Catapano A, Graham I, De Backer G et al (2016) ESC/EAS, guidelines for the management of dyslipidaemias. Eur Heart J 37:2999–3058. doi: 10.1093/eurheartj/ehw272

Kostner KM, März W, Kostner GM (2013) When should we measure lipoprotein(a)? Eur Heart J 34:3268–3270

Kronenberg F, Utermann G (2013) Lipoprotein(a) resurrected by genetics. J Intern Med 273:6–30

Kronenberg F, Lingenhel A, Lhotta K et al (2004) Lipoprotein(a) and low density-derived cholesterol in nephrotic syndrome. Kidney Int 66:348–394

Marcovina SM, Albers JJ (2016) Lipoprotein (a) measurement for clinical application. J Lipid Res 57:526–537

Cuchel M, Meagher EA, du Toit TH et al (2013) Efficacy and safety of a microsomal triglyceride transfer protein inhibitor. Lancet 381:40–46

Crooke ST, Geary RS (2013) Clinical pharmacological properties of mipomersen (Kynamro),a second generation antisense inhibitor of apolipoprotein B. Br J Clin Pharmacol 76:269–276. doi: 10.1111/j.1365-2125.2012.04469.x

Santos R, Raal F, Catapano A et al (2015) Mipomersen, an antisense oligonucleotide to apolipoprotein B100, reduces lipoprotein(a) in various populations with hypercholesterolemia. Arterioscler Thromb Vasc Biol 35:689–699. doi: 10.1161/atvbaha.114.304549

Desai N, Kohili P, Giugliano R et al (2013) AMG145, a monoclonal antibody against PCSK9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy. Circulation 128:962–969

Gaudet D, Gerald F, Watts et al (2017) Effect of alirocumab on lipoprotein(a) over ≥1.5 Years. Am J Cardiol 119:40–46. doi: 10.1016/j.amjcard.2016.09.010

Tsimikas S, Viney NJ, Hughes SG et al (2015) Antisense therapy targeting apolipoprotein (a): a randomized, doubleblind placebo-controlled phase I study. Lancet 386:1472–1483

Bundesausschuss der Ärzte und Krankenkassen (2013) Richtlinie zu Untersuchungs- und Behandlungsmethoden der vertragsärztlichen Versorgung (MVV-RL) Durchführung der Apheresen als extrakorporales Hämotherapieverfahren. BAnz AT B7:1–3 (08.04.2013)

Jaeger BR, Richter Y, Nagel D et al (2009) Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med 6:229–239

For the Pro(a)Life-study group, Leebmann J, Röseler E, Julius U et al (2013) Lipoprotein apheresis in patients with maximally tolerated lipid lowering therapy, Lp(a)-hyperlipoproteinemia and progressive cardiovascular disease – a prospective observational multicenter study. Circulation 128:2567–2567

Rosada A, Kassner U, Vogt A et al (2014) Does regular lipid apheresis in patients with isolated elevated lipoprotein(a) levels reduce the incidence of cardiovascular events? Artif Organs 38:135–141

Von Dryander M, Fischer S, Passauer J et al (2013) Differences in the atherogenic risk of patients treated by lipoprotein apheresis according to their lipid pattern. Atheroscler Suppl 14:39–44

Heigl F, Hettich R, Lotz N et al (2015) Efficacy, safety and tolerability of long-term lipoprotein apheresis in patients with LDL- or Lp (a)-hyperlipoproteinamia. Atheroscler Suppl 18:154–163

Roeseler E, Julius U, Heigl F et al (2016) Lipoprotein apheresis for lipoprotein(a)-associated cardiovascular disease: prospective 5 years of follow-up and apolipoprotein(a) characterization. Arterioscler Thromb Vasc Biol 36:2019–2202

Kassenärztliche Bundesvereinigung (2016) KBV-Qualitätsbericht Ausgabe 2015 Berichtsjahr 2014. www.kbv.de/media/sp/KBV_Qualitaetsbericht_2014.pdf

Kiechl S, Willeit J, Mayr M et al (2007) Oxydised phospholipids,lipoprotein(a),lipoprotein-associated phospholipase A2 activity and 10-year cardiovascular outcome. Prospective results from the Bruneck study. Arterioscler Thromb Vasc Biol 27:1788–1795

Kamstrup P, Benn M, Tybaerg-Hansen A et al (2008) Extreme lipoprotein(a) levels and risk of myocardial inforation in the general population. The Copenhagen City Heart study. Circulation 117:176–184

Clarke R, Peden JF, Hopewell JC et al (2009) Procardis consortium. Genetic variants associated with Lp(a) level and coronary heart disease. N Engl J Med 361:2518–2528

Cremer P, Nagel D, Labrot B (1994) Lipoprotein(a) as a predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors. Results of the Goettingen Incidence and prevalence study (Grips). Eur J Clin Invest 24:444–453

Von Eckardstein A, Schulte H, Cullen P, Assmann G (2001) Lipoprotein (a) further increases the risk of coronary events in men with high cardiovascular risk. J Am Coll Cardiol 37:434–439

Parhofer K (2007) Schwere Dyslipoproteinämie-Strategien zu Diagnostik und Therapie. UniMed, Bremen. ISBN 978-3895992322

Kraft H, Utermann A (2007) Lipoprotein(a). In: Schwandt P, Parhofer K (eds) Handbuch der Fettstoffwechselstörungen. Schattauer, Stuttgart, pp 216–230

Sechi LA, Catena C, Casaccio D, Zigaro L (2000) Lipoprotein (a) haemostatic variables and cardiocascular damage in hypertensive patients. J Hypertens 18:709–716

Yussuf S (2002) Commentary: two decades of progress in preventing cardiovascular disease. Lancet 360:2–3

Alonso-Coello P, Bellmunt S, McGrorian C et al (2012) Antithrombotic therapy in peripheral artery disease: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141:e669–e690

S3 Leitlinie _Teil 1:Sekundärprophylaxe ischämischer Schlaganfall und transitorische ischämische Attacke online www.dyn.org/images/red_leitlinien/LL-2014/pdf-Download/030-133_kurz-S3-Sekundärprophylaxe_ischämischer_Schlaganfall_2015-02.pdf

Piepoli M, Hoes A, Agewall S et al (2016) European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 37:2315–2381. doi: 10.1093/eurheartj/ehw106

Zhang XL, Zhu QQ, Zhu L et al (2015) Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials. BMC Med 13:123

Gibson C, Mehran R, Bode C et al (2016) Prevention of bleeding in patients with atrial fibrillation undergoing PCl. N Engl J Med 375:2423–2435

Hokanson JE, Austin MA (1996) Plasma triglyceride level is a risk factor independent of high density cholesterol. A meta-analysis of population-based prospective studies. J Cardiovasc Risk 3:213–219

Wayne T (2012) A review of the role of anticoagulation in the treatment of peripheral arterial disease. Int J Angiol 21:187–189